The ‘about’ BBB portion of recent press releas
Post# of 148288
(Total Views: 584)
Posted On: 10/27/2020 1:07:46 AM
The ‘about’ BBB portion of recent press releases began appearing this morning. multiple sclerosis, Parkinson's disease, CNS tumors, traumatic brain injury, and stroke recovery being at the end.
International eyeballs will be reading this for the first time in the next few hours. Makes this Monday a little friggin better. Nice development in my opinion.
“An important recent discovery of leronlimab is the ability to cross the blood-brain barrier to treat diseases where CCR5 antagonism may benefit the central nervous system. In a study of HIV in macaques, it was determined that the administration of leronlimab resulted in approximately 70-75% CCR5 receptor occupancy in the frontal lobes, parietal lobes, and cerebellum. Independent research on CCR5 antagonism in central nervous system pathology has shown promise in various disease processes, including multiple sclerosis, Parkinson's disease, CNS tumors, traumatic brain injury, and stroke recovery”
International eyeballs will be reading this for the first time in the next few hours. Makes this Monday a little friggin better. Nice development in my opinion.
“An important recent discovery of leronlimab is the ability to cross the blood-brain barrier to treat diseases where CCR5 antagonism may benefit the central nervous system. In a study of HIV in macaques, it was determined that the administration of leronlimab resulted in approximately 70-75% CCR5 receptor occupancy in the frontal lobes, parietal lobes, and cerebellum. Independent research on CCR5 antagonism in central nervous system pathology has shown promise in various disease processes, including multiple sclerosis, Parkinson's disease, CNS tumors, traumatic brain injury, and stroke recovery”
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼